Injection-free exenatide improves diabetes markers

10/3/2012 | Healio

Type 2 diabetes patients who received the injection-free exenatide ITCA 650 attained significant improvements in body weight, A1C, fasting plasma glucose and postprandial glucose levels, with greater effects seen in those who received higher doses than those who took a lower dose. However, researchers said 40 mcg and 60 mcg doses of ITCA 650 were better tolerated compared with the 80 mcg dose. The findings were presented at the European Association for the Study of Diabetes meeting.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA